U.S. Sen. John Fetterman (D-PA) is claiming that a weight-loss drug has changed his life. 

Fetterman made the claim in an op-ed that he had published recently in the New York Times. It is titled, "John Fetterman: This drug changed my life. More Americans need access."

In the piece, he describes not only how the drug changed his life, but also calls upon President Donald Trump to take action to make the drug more available for Americans.

It, however, appears unlikely that Trump will grant the senator's request. Read on to see why.

"I feel decades younger."

As you may have guessed, the kind of drugs that Fetterman is referring to are GLP-1s. This would include the likes of Ozempic and Wegovy, among others. The particular drug that appears to have helped Fetterman is Mounjaro.

Fetterman, in the op-ed, writes:

In July, I was prescribed a drug called Mounjaro. As a stroke survivor, I was interested in studies showing it could significantly reduce the risk of major cardiac events. Mounjaro is used to treat Type 2 diabetes, and a version recently received Food and Drug Administration approval for weight loss.

The senator goes on to describe the positive effects that he says came from taking the drug.

He writes:

Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health. Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I’ve also lost around 20 pounds.

Perhaps at this point, it is worth mentioning that Fetterman claims that he is "not being compensated for talking about my treatment in any way, whatsoever."

Fetterman's plea to Trump

Elsewhere in the op-ed, Fetterman makes his plea to Trump, encouraging him to take action to make such drugs available to more Americans.

Fetterman explains part of the reason why they are not more available, writing, "Without insurance coverage, drugs like Ozempic, Wegovy, and Mounjaro are prohibitively expensive — up to $1,000 every month."

Fetterman goes on to mention how former President Joe Biden, in November, put forth a rule that "would have expanded coverage for an estimated 3.4 million Americans who use Medicare and four million more on Medicaid, reducing out-of-pocket costs by as much as 95 percent."

Trump, however, upon taking office, axed this rule.

So, unless Trump suddenly changes his mind, it would appear that Fetterman's plea will not be granted.